Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Alterity Therapeutics Ltd. (PRNAF)
:PRNAF
Holding PRNAF?
Track your performance easily
PRNAF Stock Chart & Stats
Day’s RangeN/A
52-Week Range― - ―
Previous CloseN/A
Volume10.00K
Average Volume (3M)0.00
Market Cap
$26.35M
Enterprise Value$5.28M
Total Cash (Recent Filing)$21.93M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.64
Next Earnings
Feb 27, 2025Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding5,320,336,000
10 Day Avg. Volume0
30 Day Avg. Volume0
Standard Deviation2.81
R-Squared0.00007
Alpha0.72
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2162.28
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-1.40
Enterprise Value/Market Cap0.20
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Alterity Therapeutics Ltd. News
PremiumCompany Announcements
Alterity Therapeutics Director Acquires Additional OptionsPremiumCompany Announcements
Alterity Therapeutics Issues 170M Unlisted Options
PremiumCompany Announcements
Alterity Therapeutics Advances with ATH434 Trial Completion
PremiumCompany Announcements
Alterity Therapeutics Advances Amid Successful AGMRisk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PRNAF FAQ
What was Alterity Therapeutics Ltd.’s price range in the past 12 months?
Currently, no data Available
What is Alterity Therapeutics Ltd.’s market cap?
Alterity Therapeutics Ltd.’s market cap is $26.35M.
When is Alterity Therapeutics Ltd.’s upcoming earnings report date?
Alterity Therapeutics Ltd.’s upcoming earnings report date is Feb 27, 2025 which is in 39 days.
How were Alterity Therapeutics Ltd.’s earnings last quarter?
Alterity Therapeutics Ltd. released its earnings results on Feb 28, 2024. The company reported -$0.001 earnings per share for the quarter, missing the consensus estimate of $0 by -$0.001.
Is Alterity Therapeutics Ltd. overvalued?
According to Wall Street analysts Alterity Therapeutics Ltd.’s price is currently Overvalued.
Does Alterity Therapeutics Ltd. pay dividends?
Alterity Therapeutics Ltd. does not currently pay dividends.
What is Alterity Therapeutics Ltd.’s EPS estimate?
Alterity Therapeutics Ltd.’s EPS estimate is 0.
How many shares outstanding does Alterity Therapeutics Ltd. have?
Alterity Therapeutics Ltd. has 5,320,336,000 shares outstanding.
What happened to Alterity Therapeutics Ltd.’s price movement after its last earnings report?
Alterity Therapeutics Ltd. reported an EPS of -$0.001 in its last earnings report, missing expectations of $0. Following the earnings report the stock price went up 100%.
Which hedge fund is a major shareholder of Alterity Therapeutics Ltd.?
Currently, no hedge funds are holding shares in PRNAF
---
Alterity Therapeutics Ltd. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
PRNAF Sentiment 70%
Sector Average 71%
Sector Average 71%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
-102.86%
Trailing 12-Months
Asset Growth
-29.40%
Trailing 12-Months
Company Description
Alterity Therapeutics Ltd.
Alterity Therapeutics Ltd. engages in the development of therapeutic drugs designed to treat the underlying causes of degeneration of the brain as the aging process progresses. It focuses on Parkinson's movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.
---
Annovis Bio
―
Adaptimmune Therapeutics
―
Brainstorm Cell Therapeutics
―
Cellectar Biosciences
―
Geron
―
Novartis
―
---